The tweet was deleted by the author.
But we saved everything 🙂.
Syndax Pharmaceuticals has announced a significant milestone in its research efforts with the acceptance of 23 abstracts, including six oral presentations, for the upcoming 67th American Society of Hematology (ASH25) Annual Meeting.
This development underscores the ongoing promise and potential impact of Syndax's research activities. The diverse range of topics covered by these presentations is set to reveal valuable insights into the field of hematology. The ASH Annual Meeting is a prestigious event that attracts global leaders in blood disease research, making this acceptance an important achievement for Syndax Pharmaceuticals.